It plays a key role in regulating blood sugar, insulin secretion, and appetite
Medicare beneficiaries who are already receiving coverage from their Part D plan for a GLP-1 for a Medicare-covered use, such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, will continue to access the drug through their Part D plan and not through the Medicare GLP-1 Bridge, which will only provide coverage of GLP-1s when used for obesity
[DOI] [PMC free article] [PubMed] [Google Scholar] 32.Gejl M., Gjedde A., Egefjord L., Mller A., Hansen S.B., Vang K., Rodell A., Brndgaard H., Gottrup H., Schacht A., et al
Retatrutide is not "a GLP-1" in the narrow sense